Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Sensitive skin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    85 result(s) found for: Sensitive skin. Displaying page 1 of 5.
    1  2  3  4  5  Next»
    EudraCT Number: 2011-002284-14 Sponsor Protocol Number: 1528 Start Date*: 2012-03-14
    Sponsor Name:Schur Pharmazeutika GmbH & Co. KG
    Full Title: Subacute local tolerance of an ointment containing 0.5% neomycin sulfate (Myacyne Salbe)
    Medical condition: Sensitive skin areas under non-occlusive and occlusive conditions
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001276-56 Sponsor Protocol Number: AIDA Start Date*: 2014-07-11
    Sponsor Name:North Bristol NHS - Southmead Hospital
    Full Title: A prospective, open label, randomised controlled clinical trial, with pharmacokinetic-pharmacodynamic validation, to compare antimicrobial treatment with oral minocycline plus rifampicin to treatme...
    Medical condition: Complicated Skin and Skin Structure infections caused by Methicillin Resistant Staphylococcus Aureus
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-018849-59 Sponsor Protocol Number: GMIHO-008/2009_AG56 Start Date*: 2011-05-10
    Sponsor Name:GMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie mbH
    Full Title: A randomized phase II trial of standard carboplatin-based chemotherapy with or without panitumumab in platinum-sensitive recurrent ovarian cancer
    Medical condition: Platinum-sensitive recurrent ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10033131 Ovarian carcinoma LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-002669-45 Sponsor Protocol Number: ICL-23-ABSSSI1 Start Date*: 2016-02-18
    Sponsor Name:Motif BioSciences Inc.
    Full Title: A Phase 3, randomized, double-blind, multicenter study to evaluate the safety and efficacy of intravenous iclaprim versus vancomycin in the treatment of acute bacterial skin and skin structure infe...
    Medical condition: Acute bacterial skin and skin structure infections (ABSSSIs) suspected or confirmed to be due to Gram-positive pathogens.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10040872 Skin infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) DE (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2015-002687-16 Sponsor Protocol Number: ICL-24-ABSSSI2 Start Date*: 2016-05-05
    Sponsor Name:Motif BioSciences Inc.
    Full Title: A Phase 3, randomized, double-blind, multicenter study to evaluate the safety and efficacy of intravenous iclaprim versus vancomycin in the treatment of acute bacterial skin and skin structure infe...
    Medical condition: Acute bacterial skin and skin structure infections (ABSSSIs) suspected or confirmed to be due to Gram-positive pathogens.
    Disease: Version SOC Term Classification Code Term Level
    19.1 10021881 - Infections and infestations 10040872 Skin infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) BE (Completed) HU (Completed) PT (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2015-002159-89 Sponsor Protocol Number: NLD-PEG-14-10784 Start Date*: 2015-11-05
    Sponsor Name:Biogen MA
    Full Title: Brimonidine Tartrate for the Treatment of Injection Related Erythema Associated with Sub-cutaneous Administration of Peginterferon beta-1a
    Medical condition: Erythema at injection site after Plegridy injection for the treatment of Multiple Sclerose.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-003542-36 Sponsor Protocol Number: LPS16763 Start Date*: 2021-01-19
    Sponsor Name:Sanofi-aventis Recherche & Développement
    Full Title: A multi-center, exploratory study to assess dupilumab effect on pruritus neuro-mechanisms in patients with atopic dermatitis
    Medical condition: Atopic Dermatitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10012438 Dermatitis atopic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-002601-57 Sponsor Protocol Number: MK-3475-913 Start Date*: 2018-12-10
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 3 Open-label, Single Arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) as First-line Therapy in Participants With Advanced Merkel Cell Carcinoma (KEYNOTE-913))
    Medical condition: Unresectable Stage III and Stage IV Merkel Cell Carcinoma (MCC)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10064025 Merkel cell carcinoma LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FR (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-002302-43 Sponsor Protocol Number: CHDR1209 Start Date*: 2012-06-08
    Sponsor Name:Dr. Reddy's Laboratories Ltd.
    Full Title: A study to investigate the analgesic effects of buprenorphine and milnacipram in healthy volunteers.
    Medical condition: Pain therapeutics, neuropathic pain, nociceptive pain, synergism between opioids and TCA.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10054095 Neuropathic pain LLT
    14.1 10018065 - General disorders and administration site conditions 10066714 Acute pain LLT
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2005-003630-18 Sponsor Protocol Number: ICLA-09-CSI2 Start Date*: 2006-01-31
    Sponsor Name:Arpida AG
    Full Title: Phase 3, Randomized, Investigator-Blind, Multi-Center Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Intravenous Linezolid in Complicated Skin and Skin Structure Infections
    Medical condition: Complicated skin and skin structure infections are predominantly caused by the following Gram-positive pathogens: Staphylococcus aureus, including methicillin-resistant strains, beta hemolytic stre...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10040786 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) GB (Completed) DE (Completed) LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-006613-10 Sponsor Protocol Number: TMC207LEP3001 Start Date*: 2024-08-13
    Sponsor Name:Janssen Pharmaceutica NV
    Full Title: A Phase 3, Multicenter, Open-label, Rater-blind, Active-controlled Study to Evaluate the Efficacy and Safety of Bedaquiline for the Treatment of Multibacillary Leprosy When Combined With Rifampicin...
    Medical condition: Multibacillary Leprosy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10024232 Leprosy, unspecified LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2005-001548-21 Sponsor Protocol Number: ICLA-08-CSI1 Start Date*: 2005-06-21
    Sponsor Name:Arpida AG
    Full Title: Phase 3, Randomized, Investigator-Blind, Multi-Center Study to Evaluate Efficacy and Safety of Intravenous Iclaprim versus Intravenous Linezolid in Complicated Skin and Skin Structure Infections
    Medical condition: Complicated skin and skin structure infections are predominantly caused by the following Gram-positive pathogens: Staphylococcus aureus, including methicillin-resistant strains, beta hemolytic stre...
    Disease: Version SOC Term Classification Code Term Level
    7.0 10040786 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002921-20 Sponsor Protocol Number: CLS001-CO-PR-006 Start Date*: 2015-11-16
    Sponsor Name:Cutanea Life Sciences, Inc.
    Full Title: A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety of Omiganan Topical Gel in Subjects with Rosacea
    Medical condition: Papulopustular Rosacea
    Disease: Version SOC Term Classification Code Term Level
    19.1 10040785 - Skin and subcutaneous tissue disorders 10039218 Rosacea PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Ongoing) SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004800-71 Sponsor Protocol Number: 1230_OPBG_2016 Start Date*: 2017-04-07
    Sponsor Name:Bambino Gesù Children's Hospital
    Full Title: Determination of intraoperative levels of Cefoxitin during cardiac surgery requiring cardiopulmonary bypass in neonates, infants, children below, and above 40 kg.
    Medical condition: Antibiotic prophylaxis for surgical procedure using cardiopulmonary bypass in children with congenital heart disease.
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004610-42 Sponsor Protocol Number: QA351 Start Date*: 2012-01-24
    Sponsor Name:London School of Hygiene and Tropical Medicine
    Full Title: Evaluation of topical ibuprofen and steroid in the reduction of local reactions and symptoms from an Aedes aegypti mosquito bite
    Medical condition: Inflamatory reaction to a mosquito bite
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-004205-12 Sponsor Protocol Number: 792 Start Date*: 2019-02-13
    Sponsor Name:Region Skåne
    Full Title: Methylprednisolone injection in treatment of birch pollen induced allergic rhinitis
    Medical condition: Seasonal birch pollen induced allergic rhinitis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-004349-18 Sponsor Protocol Number: M-14789-41 Start Date*: 2022-07-14
    Sponsor Name:Almirall, S.A.
    Full Title: A Phase 4, Multi-centre, Randomized, Evaluatorblinded, Active-controlled Study to Determine the Incidence of Squamous Cell Carcinoma and Evaluate the Long-term Safety of Tirbanibulin 10 mg/g Ointme...
    Medical condition: Actinic Keratosis on the Face or Scalp
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10000614 Actinic keratosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Trial now transitioned) FR (Trial now transitioned) DE (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-003933-32 Sponsor Protocol Number: A092358 Start Date*: 2011-09-21
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge
    Full Title: A randomised, blind, placebo controlled crossover study of the influence of the HCN channel-blocker ivabradine on the symptoms of neuropathic pain
    Medical condition: Neuropathic Pain
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10029223 Neuralgia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2019-002644-24 Sponsor Protocol Number: DIA-STA--11-01-19 Start Date*: 2020-03-11
    Sponsor Name:Diater, Laboratorio de Diagnóstico y Aplicaciones Terapéuticas S.A.
    Full Title: Biological standarization of allergic extracts of will grasses: Phleum pratense, Lolium perenne, Poa pratensis y Dactylis glomerata and its mixture to determinate their biological activity, the In ...
    Medical condition: Biological standarization for allergenic extracts in patients with hipersensibility to extract
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10001708 Allergic conditions HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2022-001114-19 Sponsor Protocol Number: IB2022-01 Start Date*: 2023-04-03
    Sponsor Name:Institut Bergonié
    Full Title: Lurbinectedin combined with durvalumab (MEDI 4736) in pre-treated patients with extensive stage small-cell lung cancer
    Medical condition: platinum sensitive extensive stage small cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 18:15:30 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA